Introduction {#S0001}
============

Inpatient hospital stays requiring time in the intensive care unit (ICU) are approximately 2.5 times more expensive than non-ICU inpatient stays in the United States (US).[@CIT0001] In 2011, approximately 27% of the hospital stays across the US involved time in the ICU, which accounted for 48% of aggregate charges from the hospital.[@CIT0001] Across the 29 states providing data on inpatient and ICU discharges, these charges amounted to over \$280 million.[@CIT0001]

At any given time in the ICU, approximately one-third of beds are used by patients requiring mechanical ventilation (MV).[@CIT0002],[@CIT0003],[@CIT0005] Based on an analysis of ICU costs for stays with and without MV, the mean incremental costs associated with MV per day in the ICU have previously been estimated at \$1,522 per day, and thus can be a significant cost burden to the institution.[@CIT0002],[@CIT0003]

Medications for sedation are routinely administered to critically ill patients treated in the ICU for a number of reasons, including to improve synchrony with or tolerance of MV.[@CIT0006]--[@CIT0009] The 2018 clinical practice guidelines from the Society of Critical Care Medicine (SCCM) recommend that light sedation be used in critically ill, mechanically ventilated adults.[@CIT0007] Guidelines also generally recommend the use of nonbenzodiazepine sedatives (eg, propofol or dexmedetomidine) vs the use of benzodiazepine sedatives (eg, midazolam or lorazepam) in critically ill, mechanically ventilated patients because of the potential for improved short-term outcomes such as ICU length of stay (LOS), duration of MV, and delirium.[@CIT0007],[@CIT0010] Other literature have suggested benzodiazepines use in ICUs.[@CIT0011],[@CIT0012] Improvements in MV technologies and guideline support for the minimization of depth and duration of sedation suggest that use of short-acting agents, such as propofol or dexmedetomidine, may increase in the future.[@CIT0004],[@CIT0007]

Several clinical trials have compared dexmedetomidine directly with midazolam and propofol for use in the ICU for short-term sedation (\< 24 hours).[@CIT0009],[@CIT0013]-[@CIT0023] These studies suggest that dexmedetomidine is associated with shorter ICU stays and decreased MV time, potentially contributing to decreased costs and improved patient satisfaction.[@CIT0009],[@CIT0013]--[@CIT0016],[@CIT0018],[@CIT0020]--[@CIT0022],[@CIT0024],[@CIT0025] A larger clinical trial conducted in the US comparing dexmedetomidine to both propofol and midazolam also reported a reduction in intubation time and overall ICU/hospital LOS when dexmedetomidine was used.[@CIT0018]

To better understand the potential cost implication of these reported outcomes, we conducted a cost-minimization analysis from the hospital perspective of the impact of sedative choice for patients requiring MV for short-term sedation.

Methods {#S0002}
=======

The cost minimization analysis was conducted from the hospital perspective to reflect costs incurred by an institution for a single ICU stay requiring MV and short-term sedation (\<24 hours) of dexmedetomidine, propofol, or midazolam. The model was developed using Microsoft Excel^®^ 365 (2016) and Visual Basic for Applications.

Base Model Inputs {#S0002-S2001}
-----------------

Clinical Inputs: A targeted literature search of clinical trials, systematic reviews, and meta-analyses was completed to identify clinical trials comparing dexmedetomidine to either propofol or midazolam. The 16 meta-analyses and 48 clinical trials identified were reviewed for sample size, comparators, short-term sedation focus and inclusion of key outcomes of interest (ie, ICU LOS, duration of MV, sedative duration, and use of rescue sedation and pain medications). A trial conducted and published by Maldonado et al (2009)^18^ (N=90) best met key criteria and was selected to supply the clinical inputs for the base case analysis. This trial enrolled and randomized patients in a large, US tertiary-care medical center to receive dexmedetomidine, propofol, or midazolam following the successful weaning from cardio-pulmonary bypass.[@CIT0018] It was one of the few studies that included all three sedatives within one study, had substantial sample size compared to other identified trials, and measured all key outcomes of interest. Other trials were more limited (eg, geography, sample size) but were included in the sensitivity analysis to test the robustness of results.

Resource Utilization Inputs: Resource utilization inputs included ICU LOS, MV duration, sedative duration, use of rescue sedation and analgesic medications, and the treatment of adverse events (ie, bradycardia, delirium, hypertension, infection, and low blood pressure). Drug and toxicology testing (for benzodiazepines), routine monitoring (eg, respiratory monitoring, physician visits, and intubation), and time spent preparing medications were included as well. [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"} summarize the resource utilization inputs and assumptions on frequency for monitoring and management activities for the base-case analysis.Table 1Key Model Input ParametersParameterDexmedetomidinePropofolMidazolamData Source**Patient weight (kg)**82.582.582.5Average weight of an adult in the US, Centers for Disease Control and Prevention[@CIT0020]**Length of stay in ICU (days)**1.93.03.0Maldonado et al[@CIT0016]**Duration of MV (days)**0.4960.4630.529Intubation time, Maldonado et al[@CIT0016] **Sedative** Treatment duration (hours)131110Maldonado et al[@CIT0016] % that receive loading dose (%)10000Assumption based on study protocol, Maldonado et al[@CIT0016] Loading dose (µg/kg)0.4---- Duration of loading dose (min)10----Assumption based on prescribing information[@CIT0022] Maintenance dose (µg/kg/hr or mg/kg/hr)^a^0.351.5780.018Calculated dose for midazolam based on average patient weight used in model, Maldonado et al[@CIT0016] Time to prepare one bag of sedative (seconds)^b^35--35Assumption based on time to prepare one emergency syringe, Fraind et al[@CIT0025] and Jelacic et al[@CIT0038]**Pain medication** Total dose of morphine (mg)50.351.6122.5Maldonado et al[@CIT0016]**Adverse events** Occurrence of delirium (%)10.044.442.5ITT population, Maldonado et al[@CIT0016][^1][^2] Table 2Cost InputsVariablesCost (2018)Data Source**ICU room and board, cost per day** Day 1\$11,421.91Dasta et al[@CIT0003] Day 2\$5,989.35Dasta et al[@CIT0003] Day 3+\$5,454.83Dasta et al[@CIT0003]**MV, cost per day** Day 1\$7,070.38Dasta et al[@CIT0003] Day 2\$2,227.16Dasta et al[@CIT0003] Day 3+\$1,343.15Dasta et al[@CIT0003]**Sedative preparation** Pharmacist hourly rate\$55.23Society of Critical Care Medicine[@CIT0024]**Respiratory monitoring costs** Arterial blood gases, per ICU day\$26.07CPT 82,803, Blood gases any combination, CMS[@CIT0026]**Physician consultation cost, per ICU day**\$226.80CPT 99,291, Critical care first 30--74 minutes, CMS[@CIT0027]**Tracheal intubation cost, per ICU stay**\$155.52CPT 31,730, Introduction of indwelling tube for oxygen therapy[@CIT0027]**Toxicology testing** Benzodiazepine testing cost, per ICU treatment day if primary sedative was midazolam, per ICU stay if midazolam is administered for rescue sedation only\$71.83CPT 80,307, Drug test by chemistry analyzers[@CIT0026]**Medication costs (wholesale acquisition cost per vial)** Dexmedetomidine\$42.00200 µg vial, Truven Health Analytics[@CIT0028] Midazolam\$1.9250 mg vial, Truven Health Analytics[@CIT0028] Midazolam\$0.555 mg vial for rescue sedation, Truven Health Analytics[@CIT0028] Propofol\$3.88500 mg vial, Truven Health Analytics[@CIT0028] Morphine\$7.05250 mg vial, Truven Health Analytics[@CIT0028] Atropine, 0.5 mg per bradycardia event\$1.611 mg vial, Truven Health Analytics[@CIT0028] Haloperidol, 10 mg per delirium event\$0.885 mg vial, Truven Health Analytics[@CIT0028] Labetalol, 20 mg per hypertension event\$3.35100 mg vial, Truven Health Analytics[@CIT0028] Norepinephrine, 4 mg per hypotension event\$4.604 mg vial, Truven Health Analytics[@CIT0028] Cefazolin, 1 g per infection event\$6.332 g vial, Truven Health Analytics[@CIT0028][^3]

Cost Inputs: Unit cost inputs for the model included medical resource utilization unit costs (including ICU LOS, MV duration, monitoring, and management), drug costs, and sedative preparation time. Cost inputs and cost-related assumptions included in the model were based on published data and are summarized in [Table 2](#T0002){ref-type="table"}. Medical care resource unit costs as well as costs associated with the preparation of sedatives were obtained from the published literature,[@CIT0003],[@CIT0026],[@CIT0027] and estimated based on Current Procedural Terminology (CPT^®^) codes and the corresponding physician and clinical laboratory fee schedules.[@CIT0028],[@CIT0029] Costs for adverse events were based on the treatments described in [Table 2](#T0002){ref-type="table"} and assumed that only a single round of treatment was required per adverse event episode. Wholesale acquisition cost was used for any medication-related resource utilization in the model (eg, sedatives, analgesics, treatments for adverse events).[@CIT0030] All costs were adjusted to 2018 US Dollars using the medical component of the Consumer Price Index.[@CIT0031]

Sensitivity Analysis Inputs {#S0002-S2002}
---------------------------

To estimate the robustness of the baseline results, a univariate sensitivity analysis was performed using the clinical outcomes from other published clinical trials comparing dexmedetomidine to propofol or midazolam.[@CIT0013]--[@CIT0016],[@CIT0019],[@CIT0032] Since not all trials compared dexmedetomidine to both propofol and midazolam, the sensitivity analysis was performed separately for the comparison of dexmedetomidine to propofol and dexmedetomidine to midazolam. The range of inputs used in the sensitivity analysis for each of the input parameters is summarized in [Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"}. Each clinical input was varied to reflect the minimum and maximum values described in the published literature. If alternative values were not identified in the published literature (eg, cost inputs), we modified the input by 10% in the univariate sensitivity analysis.Table 3Sensitivity Analysis Clinical Inputs for Propofol ComparisonParametersDexmedetomidine ArmPropofol ArmData SourceLower ValueUpper ValueLower ValueUpper Value**Length of stay in ICU (days)**0.961.900.963.00Corbett et al,[@CIT0030] Maldonado et al[@CIT0016]**Duration of MV (days)**0.230.500.250.54Djaiani et al,[@CIT0012] Srivastava et al[@CIT0013]**Sedative** Treatment duration relative to MV duration (± hours)^a^−0.596.00−0.44−0.10Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] % that receive loading dose (%)901000100Dexmedetomidine inputs did not vary in published literature, varied by 10% for analysis. Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Loading dose (µg/kg or mg/kg/hr)^a^0.401.000.004.00Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Duration of loading dose (minutes)^a^10.0020.000.0015.00Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Maintenance dose (µg/kg/hr or mg/kg/hr)^b^0.310.550.042.00Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Srivastava et al[@CIT0013] Time to prepare bag (200 µg) of dexmedetomidine or vial of propofol (seconds)25115059Fraind et al,[@CIT0025] Jelacic et al,[@CIT0038] and van der Linden[@CIT0039]**Rescue sedation, midazolam** % that receive rescue sedation (%)01000100Corbett et al,[@CIT0030] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Rescue sedative dose (mg)01.501Corbett et al,[@CIT0030] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013]**Pain medication** % treated with pain medication (%)9010090100Inputs did not vary in published literature, varied by 10% for analysis. Corbett et al, Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Total dose of morphine (mg)2.9550.306.0051.60Corbett et al,[@CIT0030] Herr et al,[@CIT0017] Maldonado et al[@CIT0016]**Adverse events** Occurrence of bradycardia (%)0301Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Occurrence of delirium (%)012044Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Occurrence of hypertension (%)01204Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Occurrence of hypotension (%)081067Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Occurrence of infection (%)010010Inputs did not vary in published literature, varied by 10% for analysis. Corbett et al,[@CIT0030] Djaiani et al,[@CIT0012] Herr et al,[@CIT0017] Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013][^4][^5] Table 4Sensitivity Analysis Clinical Inputs for Midazolam ComparisonParametersDexmedetomidine ArmMidazolam ArmData SourceLower ValueUpper ValueLower ValueUpper Value**Length of stay in ICU (days)**1.902.733.004.23Azeem et al,[@CIT0011] Maldonado et al[@CIT0016]**Duration of MV (days)**0.190.500.520.54Azeem et al,[@CIT0011] Srivastava et al,[@CIT0013] Wan et al[@CIT0014]**Sedative** Treatment duration relative to MV duration (± hours)−0.592.80−2.70−0.80Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] % that receive loading dose (%)0%100%0%100%Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Loading dose (µg/kg or mg/kg)^a^0.001.000.000.04Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Duration of loading dose (min)0.0015.000.0015.00Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Maintenance dose (µg/kg/hr or mg/kg/hr)^b^0.350.720.020.44Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Wan et al[@CIT0014] Time to prepare one bag of sedative (sec)^c^2511525115Fraind et al,[@CIT0025] Jelacic et al,[@CIT0038] and van der Linden[@CIT0039]**Rescue sedation, midazolam**For the midazolam arm, considered in sensitivity analysis for the primary sedative % that receive rescue sedation (%)0100----Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Rescue sedative dose (mg)06.7----Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014]**Pain medication** % treated with pain medication (%)9010090100Inputs did not vary in published literature, varied by 10% for analysis. Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Total dose of morphine (mg)17.6150.3037.21125.06Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Wan et al[@CIT0014]**Adverse events** Occurrence of bradycardia (%)025010Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Occurrence of delirium (%)010043Maldonado et al,[@CIT0016] Srivastava et al[@CIT0013] Occurrence of hypertension (%)010010Inputs did not vary in published literature, varied by 10% for analysis. Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Occurrence of hypotension (%)028011Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014] Occurrence of infection (%)010010Inputs did not vary in published literature, varied by 10% for analysis. Azeem et al,[@CIT0011] Maldonado et al,[@CIT0016] Srivastava et al,[@CIT0013] Wan et al[@CIT0014][^6][^7]

Results {#S0003}
=======

The total cost per patient/per ICU stay was \$21,115 for dexmedetomidine, \$27,073 for propofol, and \$27,603 for midazolam treatment in the base-case analysis ([Table 5](#T0005){ref-type="table"}, [Figure 1](#F0001){ref-type="fig"}). Dexmedetomidine was associated with per patient/per ICU stay cost savings compared to both propofol and midazolam. Treatment costs for dexmedetomidine were \$5,958 lower compared to propofol and \$6,487 lower compared to midazolam.Table 5Base Case Results: Estimated ICU Cost Associated with Each Sedative, per PatientCost per SedativeDifference between Dexmedetomidine and ComparatorDexmedetomidinePropofolMidazolamv Propofolvs MidazolamICU Days\$16,812.33\$22,866.09\$22,866.09-\$6,053.77-\$6,053.77MV Days\$3,506.91\$3,273.59\$3,740.23\$233.32-\$233.32Monitoring/Management\$661.26\$914.13\$985.96-\$252.87-\$324.70Sedative\$127.61\$11.64\$2.46\$115.97\$125.15Rescue Sedation\$0.00\$0.00\$0.00\$0.00\$0.00Pain Medication\$7.05\$7.05\$7.05\$0.00\$0.00Adverse Event\$0.18\$0.78\$0.75-\$0.61-\$0.57**Total**\$21,115.33\$27,073.28\$27,602.54-\$5,957.95-\$6,487.21[^8] Figure 1Base case results: Essential ICU cost associated with each schedule, per patient. \*Other costs include cost of sedative, reduce sedative, pain medication, monitoring/management, and cost of adverse event treatment.**Abbreviations:** ICU, intensive care unit; MV, mechanical ventilation.

Analysis by cost component ([Table 5](#T0005){ref-type="table"}) showed that the greatest contributor to cost savings was the reduction in ICU LOS with dexmedetomidine. Additional cost reductions with dexmedetomidine compared to propofol and midazolam were observed for monitoring and management activities as well as for occurrence of adverse events. Compared to midazolam only, dexmedetomidine also contributed to a reduction of costs associated with MV.

Sensitivity Analysis {#S0003-S2001}
--------------------

When compared to midazolam, dexmedetomidine was consistently associated with a cost savings in the sensitivity analysis of the base model. These cost savings ranged from \$1,653 to \$13,702. The minimum cost savings was associated with a reduction of 0.83 days in the ICU LOS for patients receiving dexmedetomidine (1.90 days in the base-case analysis vs 2.73 days in the sensitivity analysis). The maximum cost savings was associated with a reduction of 1.23 days in the ICU LOS for patients receiving midazolam (3.00 vs 4.23 days).

The sensitivity testing of propofol found similar conclusions. Dexmedetomidine compared to propofol was associated with a maximum cost savings of \$12,081 when the ICU LOS for patients receiving dexmedetomidine was reduced by 0.94 days compared to the base case (1.90 vs 0.96 days). When LOS for patients receiving propofol was reduced to 2.04 days (3.00 vs 0.96 days), the sensitivity analysis at this lower range did find dexmedetomidine was associated with an increased cost.

Discussion {#S0004}
==========

In this model, dexmedetomidine was generally found to be associated with significant cost savings of \~\$6,000 compared to propofol and midazolam in mechanically ventilated, adult patients undergoing short-term sedation (\< 24 hours). The cost savings associated with reduced ICU LOS and required monitoring and management reflects potential economic value of dexmedetomidine.

These results are directionally consistent with multiple cost studies completed in the US for sedated mechanically ventilated patients.[@CIT0018],[@CIT0024],[@CIT0033] Previous cost studies have demonstrated that clinical outcomes associated with sedative choice can impact the overall cost of an ICU stay.[@CIT0018],[@CIT0024],[@CIT0030],[@CIT0033]--[@CIT0037] The drivers of cost savings in this analysis were also consistent with previous studies, with the key driver of high costs being the fixed room and board costs associated with the ICU stay.[@CIT0018],[@CIT0024],[@CIT0033],[@CIT0037] The absolute costs and the magnitude of the cost differences, however, differed between our analysis and previous cost studies which included mixed patient populations requiring both long-term and short-term sedation. Selection of inputs, and overall study design differences likely also contributed.

Of note, one published cost analysis in 2009 by Patanwala et al^37^ did report higher costs associated with dexmedetomidine compared to propofol for sedation in the ICU. In that analysis, total hospital costs when ICU patients were treated with dexmedetomidine were \$46,716 compared to \$31,041 in the propofol group.[@CIT0037] However, the increased LOS that drove the cost differential was not adjusted for potential unmeasured confounders, such as dosing, level of sedation, delirium screening, or rescue sedation. Additionally, there were several observed differences between the two patient populations (eg, age, sex, race, admission type, service category, and severity of illness) that may suggest selection bias for treatment with each sedative.[@CIT0037]

Nonetheless, there are important limitations to keep in mind regarding the current model. First, the base case analysis utilized clinical inputs from an open label trial. While an unblinded study design was reasonable due to the distinct physical and pharmacological properties of the chosen sedatives, the possibility of investigator bias could not be eliminated. Further, while the results of our cost-minimization analysis were informed by national costing information and tested with the range of results found within the literature via sensitivity analysis, the analysis was performed for a specific population and caution should be employed in generalizing to all MV patients. The model was fit for purpose for one country and may not be reflective of different markets, given differences in indications, utilization, and reimbursement systems. Future explorations specific to European and Asian market dynamics could further a broader global understanding. There were also cases where a few unit costs were not readily available. In lieu of this, we applied reimbursement amounts pulled from US reimbursement fee schedules. None of these cost elements were the main drivers of overall cost estimates in the model, so the impact on conclusions drawn is likely minimal.

Lastly, it is important to reflect that this model offers one perspective in the ongoing understanding and discussion of short-term sedation in the ICU. After the development of this model, new studies, such as the Spice III study have been published.[@CIT0038] While SPICE III is out of scope geographically for this current US specific model (ie, the study was conducted in eight ex-US countries that might have variations in sedative indications, utilization, and reimbursement systems), it is still important to reflect that the understanding of these dynamics within the ICU remain an evolving conversation. The results from the current analysis and their interpretation are meant to contribute and further open value and cost perspective discussions that have in the past been limited in literature.

Conclusion {#S0005}
==========

With US national healthcare spending projected to reach \$5.7 trillion by 2026[@CIT0039] and critical care accounting for about 4.1%[@CIT0040] of this spending, it is important to understand potential cost reduction opportunities in the ICU. This cost-minimization analysis suggests that choice of short-term sedation during MV may contribute to ICU LOS and associated costs. Critical care practitioners may want to consider the results of this analysis when selecting short-term sedatives for their mechanically-ventilated ICU patients.
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[^1]: **Notes:** ^a^Dexmedetomidine: µg/kg/hr; propofol and midazolam: mg/kg/hr; ^b^200 µg/bag of dexmedetomidine; 50 mg/bag of midazolam.

[^2]: **Abbreviations:** ICU, intensive care unit; ITT, intention-to-treat; LOS, length of stay; MV, mechanical ventilation; US, United States.

[^3]: **Abbreviations:** CMS, Centers for Medicare and Medicaid Services; CPT, current procedural code; ICU, intensive care unit; MV, mechanical ventilation.

[^4]: **Notes:** ^a^Dexmedetomidine: µg/kg; propofol: mg/kg/hr; ^b^Dexmedetomidine: µg/kg/hr; propofol: mg/kg/hr.

[^5]: **Abbreviations:** ICU, intensive care unit; MV, mechanical ventilation.

[^6]: **Notes:** ^a^Dexmedetomidine: µg/kg; midazolam: mg/kg; ^b^Dexmedetomidine: µg/kg/hr; midazolam: mg/kg/hr; ^c^200 µg/bag of dexmedetomidine; 50 mg/bag of midazolam.

[^7]: **Abbreviations:** ICU, intensive care unit; MV, mechanical ventilation.

[^8]: **Abbreviations:** ICU, intensive care unit; MV, mechanical ventilation; vs, versus
